CD4 and prostate cancer: On the other hand, a promising strategy based on TCR isolation for neoepitope-specific TCR cloning and engineering of autologous CD8+ and CD4+ T-cells is being implemented in clinical trials that include patients with prostate cancer (NCT03970382).